SEMG Launches Diabetosemg 2025 Algorithm for Personalized Diabetes Care

The Spanish Society of General and Family Physicians (SEMG) has presented the first edition of the Diabetosemg 2025 algorithm to primary care professionals during its XI Diabetes Training Forum and the IX Cardiovascular Conference, which took place this weekend in Toledo.

The Diabetes and Cardiovascular Disease Working Group of the SEMG (Spanish Society of Cardiovascular Disease) was responsible for developing this algorithm. The society hopes it will serve as a guide for the therapeutic approach to type 2 diabetes , using a multifactorial approach that combines pharmacological and non-pharmacological strategies such as nutrition, exercise, and lifestyle.

SEMG’s new algorithm offers primary care doctors personalized, evidence-based guidance for managing type 2 diabetes

“Beyond its technical utility, this algorithm was born from a collective desire to reach the largest number of family doctors,” they explained. With this, the SEMG (Spanish Ministry of Health) seeks to ensure that primary care professionals can benefit from a new, quick and accessible reference tool.

Using an integrated QR code, healthcare professionals can directly access downloadable content that allows for personalized diet and physical activity prescriptions, facilitating therapeutic education and interventions right from the office.

The evaluation performed by this algorithm is individualized based on the patient’s clinical condition. It takes into account factors such as frailty, obesity, chronic kidney disease, heart failure, and established cardiovascular disease, using a star-rating system that facilitates the selection of treatments with the greatest clinical benefit in each situation.

“The Diabetes Mg2025 algorithm transcends its status as a simple technical framework to become a bridge between scientific evidence and real-world clinical practice”

The infographic includes a sidebar with key recommendations for specific settings, such as end-of-life, liver disease, or extreme obesity. It also shows a lower section with medication adjustments based on glomerular filtration rate, in accordance with the most recent recommendations from the 2022 Kdigo ( Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease ) guidelines.

In turn, SEMG’s algorithm includes the treatments best positioned for their proven effectiveness in cardiovascular, renal and weight loss benefits , as evidenced by the ADA/EASD ( American Diabetes Association/European Association for the Study of Diabetes ), AACE ( Association of Clinical Endocrinology ) and ESC ( European Society of Cardiology ) guidelines.

“In this way, the Diabetosemg 2025 algorithm transcends its status as a simple technical scheme to become a bridge between scientific evidence and real-life clinical practice , with a direct impact on both the professionals who apply it and the patients who benefit from more optimal, individualized, and effective management,” the society concluded.

__

(Featured image by Sweet Life via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.